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Verotoxin (VT)-producing Escherichia coli (E. coli) O157:H7 infections are frequently complicated by thrombotic angiopathy, hemolytic
uremic syndrome (HUS) and neurological symptoms. The present data demonstrate that VT-1 (Shiga toxin) stimulation of macrophage-like THP-1
cells up-regulates the activity, antigen and mRNA levels of tissue factor (TF), a key cofactor of the coagulation–inflammation–thrombosis circuit.
This up-regulation is accompanied by phosphorylation of phosphatidylinositol 3-kinase (PI3-kinase), IκB kinase β (IKKβ) and extracellular
signal-regulated kinase 2 (ERK2). Changes in TF mRNA levels were in parallel with the activation of NF-κB/Rel and Egr-1 activation, but not
with AP-1. Inhibition of PI3-kinase attenuated VT-1-induced phosphorylation of IKKβ and ERK2, and the up-regulation of TF mRNA levels. VT-
1 stimulation rapidly activated c-Yes tyrosine kinase, a member of the Src family. Treatment of the cells with c-Yes antisense oligos attenuated the
VT-1-induced phosphorylation of PI3-kinase, IKKβ and ERK2, activations of NF-κB/Rel and Egr-1, and up-regulation of TF mRNA levels.
These results suggest that VT-1-induced macrophage stimulation activates c-Yes, which then up-regulates TF expression through activation of the
IKKβ/proteasome/NF-κB/Rel and MEK/ERK2/Egr-1 pathways via activation of PI3-kinase. Induction of macrophage TF expression by VT-1
may play an important role in the acceleration of the coagulation–inflammation–thrombosis circuit during infections by VT-producing E. coli.
© 2006 Elsevier B.V. All rights reserved.Keywords: Tissue factor; Verotoxin-1; Shiga toxin; Blood coagulation; c-Yes; NF-κB; Macrophage-like cell1. Introduction
Verotoxin (VT)-producing Escherichia coli O157:H7 (E.
coli O157) is responsible for hemorrhagic colitis and the
subsequent development of life-threatening complications,
including acute renal failure and neurological symptoms [1].
The acute renal failure caused by VTs is referred to as hemolytic
uremic syndrome (HUS) and is characterized by a glomerular
thrombotic microangiopathy with fibrin-rich thrombi [2]. This
could be caused by activation of coagulation and suppression
of fibrinolysis, since circulating levels of the thrombin–
antithrombin complex, prothrombin fragment 1+2, and plasmi-⁎ Corresponding author. Tel.: +81 42 721 1561; fax: +81 42 721 1561.
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doi:10.1016/j.bbadis.2006.07.004nogen activator inhibitor-1 (PAI-1) are elevated in these patients
[3]. VTs are thought to be essential for the development of HUS
and neurological complications, since many of the histopatho-
logical features of the renal and central nervous system (CNS)
vascular damage seen in humans can be reproduced after the
administration of purified VTs in animals [4].
VT-1 is one of several verotoxins that include VT-1, VT-2 and
variants of VT-2, and is identical to Shiga toxin produced by
Shigella dysenteriae. The VT-1 holotoxin binds with high
affinity to the glycolipid, globotriaosyl ceramide (Gb3), which is
a cellular receptor for VT-1 on various target cells, and induces
pathophysiological responses when activated [5]. Gb3 expres-
sion has been reported for various cells including renal tubular
cells, vascular endothelial cells [6], gut epithelial cells [7],
nervous system capillary cells [8], and monocyte/macrophage
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induced HUS experimental model resulted in reduction of the
inflammatory cytokine production and the lethality of the model
[10,11], which indicates that macrophages found within the
kidney and CNS play a significant role in the pathogenesis of
HUS and CNS. With regard to subcellular signaling, it has
reported that production of the inflammatory cytokines includ-
ing tumor necrosis factor (TNF)-α in VT-1-stimulated macro-
phages are correlated with activations of both p38 mitogen-
activated protein kinase (p38 MAPK) and extracellular-
regulated kinase (ERK) [12]. On the other hand, Katagiri et al.
[13] reported that c-Yes, a member of the Src family kinases, is
associated with Gb3 after VT-1 stimulation of renal tubular cells.
However, the role of c-Yes in the expression control of proteins
and the subcellular signaling in VT-1-stimulated cells has yet to
be investigated.
Tissue factor (TF) is an integral member of the cytokine
receptor family and triggers blood coagulation by binding with
the enzyme coagulation factor VIIa and the substrate factor X
[14]. In this ternary complex, Xa is generated and the liberated
Xa leads to thrombin formation and fibrin deposition. Further-
more, signals from the TF–VIIa complex enhance cell migration
via the protease-activated receptor 2 (PAR2) [15] and signals
from the TF–VIIa–Xa ternary complex and/or Xa signals
produce inflammatory cytokines via PAR1 and 2 [16]. Under
normal circumstances, TF is either not expressed or only
expressed at very low levels on the surface of endothelial cells
and monocytes/macrophages [17]. However, after stimulation
with bacterial lipopolysaccharide (LPS) and inflammatory
cytokines, there is a marked expression of TF on the cell surfaces
[18–20]. Aberrant TF expression is found in various conditions
such as inflammation, septic shock, thromboembolic disorders,
and disseminated intravascular coagulation (DIC) [21,22]. In the
E. coli-induced sepsis model, TF antibody treatment or the use of
mice that lack expression of the TF cytoplasmic domain leads to
attenuation of renal failure abnormalities, tissue neutrophil
influx, fibrin deposition, and increases in pro-inflammatory
cytokines, such as IL-6 and 8 [23,24]. This implies that TF
participates in the regulation of both the coagulation and
inflammatory processes and plays a key role in the coagula-
tion–inflammation–thrombosis circuit, which is responsible for
the subsequent development of life-threatening complications
[25]. However, there is no information about TF expression in
monocyte/macrophage lineage cells stimulated with VT-1.
Monocyte/macrophage lineage cells exhibit a different
response to VT-1 during the differentiation of these cells.
Differentiation of the THP-1 cells, a human monocytic leukemia
cell line, is initiated by treatment with phorbol 12-myristate 13-
acetate (PMA) andmimics plastic-adherentmacrophages (macro-
phage-like THP-1 cells) [26]. VT treatments of non-adherent
monocytes and undifferentiated THP-1 cells result in rapid cell
death. However, while adherent monocytes and differentiated
macrophage-like THP-1 cells, as well as macrophages, are
resistant to VT-1, they are responsible for VT-1 stimulation that
leads to a subsequent cytokine production [27]. The differentiated
macrophage-like THP-1 cells are widely used as macrophage
substitutes in experiments designed to explore the effect of VT-1on macrophages. The present study was undertaken to evaluate
whether VT-1 induces TF expression on differentiated macro-
phage-like THP-1 cells through c-Yes activation and to elucidate
the molecular basis for the transcriptional regulation of the TF
gene after VT-1 induced c-Yes activation.
2. Materials and methods
2.1. Materials
Purified VT-1 was donated by Denka Seiken Co. (Niigata, Japan). In order to
remove residual endotoxin contaminations, VT-1 was further passed through a
Detoxi-Gel column (Wako Pure Chemical Industries (Osaka, Japan)). Percoll,
Poly (dI–dC) .Poly (dI–dC), and oligonucleotides for the electrophoretic mobility
shift assay (EMSA) were obtained from Amersham Biosciences (Uppsala,
Sweden). Penicillin, streptomycin, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenylte-
trazolium bromide (MTT), rabbit brain thromboplastin and bovine serum albumin
(BSA) were purchased from Sigma Chemical (St. Louis, MO). MG132 was
obtained from the Peptide Institute (Osaka, Japan), SB203580 and LY294002
from Carbiochem-Novabiochem (San Diego, CA), PD98059 from Biomol
Research Laboratories, Inc. (PlymouthMeeting, PA), and [γ32P]ATP from Perkin
Elmer Japan (Yokohama, Japan). Unless otherwise indicated, all other reagents
were purchased from Wako Pure Chemical Industries (Osaka, Japan).
2.2. Antibodies
Mouse monoclonal anti-human TF IgG1 antibody (clone TF9-10H10) was
obtained from American Diagnostica (Greenwich, CT). The rabbit polyclonal
antibodies directed against human p65, p50, c-Rel, c-Fos, c-Jun, JunD, JunB,
Egr-1, Egr-2, Sp3, Sp4, IκB kinase α/β (IKKα/β), IKKα, phospho-PI3-kinase
(p85α) and Lyn, and the mouse monoclonal antibodies directed against human
Sp1 and c-Src were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Rabbit polyclonal anti-PI3-kinase (p85α) was obtained from Upstate
Biotechnology (Lake Placid, NY). Rabbit polyclonal anti-phospho-IKKα/β,
anti-phospho-p44/p42 MAPK (ERK1/2) and anti-ERK1/2 antibodies, mouse
monoclonal anti-phospho-p38 MAPK (28B10) and anti-p38 MAPK (5F11)
antibodies, and horse radish peroxidase (HRP)-labeled goat anti-rabbit IgG
antibody were obtained from Cell Signaling Technology (Beverly, MA). HRP-
labeled rabbit anti-mouse IgG antibody, fluorescein isothiocyanate (FITC)-
labeled rabbit anti-mouse IgG antibody and mouse monoclonal IgG1 were
from DAKO (Glostrup, Denmark). Mouse monoclonal anti-c-Yes antibody
(mAb1B7) was from Wako Pure Chemical Industries (Osaka Japan).
2.3. Cell culture and differentiation
To induce differentiation to macrophage-like THP-1 cells, human monocytic
leukemia cell line THP-1 cells (1×106 cells/ml) obtained from the American
Type Culture Collection (Rockville, MD) underwent treatment with 50 ng/ml
PMA in RPMI 1640 supplemented with penicillin (50 units/ml), streptomycin
(50 μg/ml), and 10% heat-inactivated fetal calf serum (FCS) (culture medium)
for 48 h, as previously described [29]. The differentiated macrophage-like THP-
1 cells were washed three times with cold Ca2+- and Mg2+-free phosphate-
buffered saline (PBS (−)) to remove undifferentiated cells and PMA, and then
incubated with culture medium for 3 to 4 days with daily medium changes
before use in the experiments. Human peripheral monocytes were isolated from
blood collected from healthy adult volunteers by hypotonic density gradient
centrifugation in Percoll [28]. All blood samples were obtained after informed
consent. After removal of the non-adherent cells, the adherent monocytes were
used in the experiments. Cell viability was determined by the MTT assay, as
described previously [29].
2.4. TF procoagulant activity and immunohistochemical assay of TF antigen
TF procoagulant activity in the cells (24-well plates, 1.0×106 cells/well) was
measured by a one-stage clotting assay, as described previously [20,29]. One
unit of activity was defined as a clotting time of 20 s in a standard assay with
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since procoagulant activity was not detected in the cells when factor VII- or X-
deficient plasma was used instead of normal plasma. An immunohistochemical
assay for TF antigen was performed with mouse monoclonal anti-human TF
IgG1 or mouse monoclonal IgG1, as previously described [29]. Fluorescence
was detected by microscopy (Olympus IX70, Tokyo, Japan).
2.5. TF mRNA by the reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was prepared from the cells (24-well plate, 1.0×106 cells/well)
using ISOGEN (Nippon Gene, Tokyo, Japan). Analysis of TF mRNA was
performed by RT-PCR from the RNA preparation (1 μg/sample), as previously
described [20,29]. After amplification and electrophoresis on 2% agarose gels,
the gels were stained with 0.1 μg/ml ethidium bromide and photographed under
UV light. The areas corresponding to the amplified cDNA on the gel were
quantified by densitometric scanning using an Epi-Light FA500 (Aisin Cosmos
Co., Aichi, Japan). In the range from 0.005 to 3.3 μg RNA, there was a linear
relationship between the density obtained for each PCR product and the amount
of total RNA subjected to RT-PCR.
2.6. EMSA and supershift assay
Nuclear extraction from the cells (3.0×106 cells/35-mm dish), EMSA and
supershift assay were performed as described previously [29]. Briefly, the
nuclear extracts were incubated with the following 32P-labeled double-stranded
oligonucleotide probes: TF-κB (NF-κB/Rel binding site in the TF promoter
region), 5′-AGGGTCCCGGAGTTTCCTACCGGGA-3′; distal TF-AP-1 (AP-1
binding site in the TF promoter region), 5′-TCGGTGGCGCGGTTGAAT-
CACTGG-3′; proximal TF-AP-1, 5′-GGTGAGTCATCCCTTGCAGGGTCC-
3′; a prototypic Egr-1, 5′-CCCGGCGCGGGGGCGATTTCGAGTCA-3′; a
prototypic Sp1, 5′-ATTCGATCGGGGCGGGGCGAGC-3′, with or without
antibody against various transcription factors. The protein-oligonucleotide
complexes (TF-κB- and TF-AP-1-oligonucleotide complexes) were separatedFig. 1. Increase in TF activity, antigen and mRNA levels in macrophage-like THP-1
10 ng/ml VT-1 for various times and then the procoagulant activity (A) and TF mRNA
of VT-1 (0–10 ng/ml) for 6 h (B) or 2 h (G), the procoagulant activity (B) and TF mRN
from four independent experiments. The TF mRNA levels were expressed as the relat
actin mRNA levels. (C, D, E) The cells were incubated with (D, E) or without (C) 10 n
and untreated cells were incubated with anti-TF antibody and detected with FITC-labe
monoclonal IgG1 was performed for VT-1-treated cells to assess nonspecific binding o
independent experiments.from free oligonucleotides by electrophoresis in 4% polyacrylamide gels in 1×
Tris borate EDTA (TBE) buffer. Egr-1- and Sp1-oligonucleotide complexes
were separated in 0.5× TBE buffer. The gels were dried and radiolabeled bands
were visualized by a BAS 2000-II Bio-Imaging Analyzer (Fuji Photo Film Co.,
Tokyo, Japan) or exposed to X-Omat AR film (Eastman Kodak, Rochester, NY).
2.7. Western blot analysis
Cells (3×106 cells) were lysed in lysis buffer (50 mM Tris, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 0.5 mM 4-(2-aminoethyl)-benzene sulfonyl-fluoride
hydrochloride (AEBSF), 2 μg/ml leupeptin, 2 μg/ml aprotinin, 1 μM E-64,
0.5 mM EDTA, 1 mM sodium orthovanadate). The cell lysates were boiled in
Laemmli's sample buffer (LSB) and were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in 10% gels. The separated
proteins were transferred to a polyvinylidene difluoride (PVDF) membrane,
which was incubated with primary antibody of anti-phospho-PI3-kinase, anti-
phospho-IKKα/β, anti-phospho-ERK1/2, anti-phospho-p38 MAPK, anti-PI3-
kinase, anti-IKKα/β plus anti-IKKα, anti-ERK1/2, anti-p38 MAPK, anti-cYes,
anti-c-Src, or anti-Lyn. After incubating with an HRP-labeled detection
antibody, the signal was visualized by chemiluminescence (Pierce Chemical,
Rockford, IL). Protein levels were quantified by densitometric analysis using
NIH Image software.
2.8. Immunoprecipitation and kinase assay for Src family kinase
Immunoprecipitation and the kinase assay for the Src family kinases (c-Yes,
c-Src, and Lyn) were performed after slight modification of a previously reported
method [30]. VT-1-treated and untreated cells were washed twice with ice-cold
PBS (−) and lysed in lysis buffer. The lysates (500 μg of cellular proteins) were
incubated with 2 μg of anti-c-Yes, anti-c-Src, or anti-Lyn antibody for 1 h at 4 °C.
The immune complexes were fixed on Protein G-Sepharose (KPL, Gaithersburg,
MD) for 3 h with rotation at 4 °C, followed by washing two times in lysis buffer
and two times in kinase buffer (10 mM Tris, pH 7.4, 10 mM MnCl2, 1 mM
MgCl2, 1 mM DTT, 0.1 mM sodium orthovanadate). The immunoprecipitatescells exposed to VT-1. (A, F) Macrophage-like THP-1 cells were treated with
level (F) were determined. (B, G) After incubating with various concentrations
A level (G) were determined. The data of TF activities represent the mean±S.D.
ive intensity of control values (0 h or 0 ng/ml VT-1) after normalization to the β-
g/ml VT-1 for 6 h. For immunohistochemical assays of TF antigen, VT-1-treated
led rabbit anti-mouse IgG antibody (C, D). The control experiment using mouse
f FITC-labeled antibody (E). The data (C, D, E) represent a typical result of four
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presence of 10 μM cold ATP, 1 μCi of [γ-32P]ATP, and 5 μg of acid-denatured
enolase/sample for 15 min at 25 °C. Reactions were stopped by boiling in LSB,
and proteins were separated on SDS-PAGE (10% gels). The kinase activity for
incorporation of [γ-32P]ATP into enolase, c-Yes, c-Src, or Lyn was measured by
autoradiography. The amount of c-Yes, c-Src, or Lyn applied for the kinase assay
was estimated by Western blotting with anti-c-Yes, anti-c-Src, or anti-Lyn as the
primary antibody.
2.9. c-Yes antisense oligonucleotide experiments
c-Yes phosphorothioate antisense (c-Yes AS) and its corresponding control
randomized sequence phosphorothioate oligonucleotide (CS) were designed and
manufactured by Biognostik (Gottinggen, Germany). These oligonucleotides
were used according to the manufacturer's instructions. Macrophage-like THP-1
cells and peripheral adherent monocytes were exposed for 24 or 48 h to 4 μM of
c-Yes AS or CS in RPMI containing 1% FCS. The c-Yes levels in the cell lysates
were estimated by Western blotting.
3. Results
3.1. TF activity and mRNA levels in macrophage-like THP-1
cells treated with VT-1
At 24 h after treatment with 0.1 to 10 ng/ml VT-1, over 90%
of the MTT reducing activity of the macrophage-like THP-1
cells was maintained as compared to untreated controls (data not
shown). The effect of VT-1 on TF activity in differentiatedFig. 2. Effects of inhibitors on VT-1-induced activation of NF-κB/Rel, AP-1, or Eg
cells. (A, B, C) Macrophage-like THP-1 cells were pretreated with or without
stimulation of 10 ng/ml VT-1 for 2 h. The nuclear proteins extracted from the cell
(A-2, B-2, C-2), or Egr-1 (A-3, B-3, C-3) oligonucleotide. EMSAs were perform
levels were determined by RT-PCR (A-4, B-4, C-4). The data represent a typicalmacrophage-like THP-1 cells was time-dependent. Relative to
untreated control cells, a 4.4-fold increase in TF activity was
observed 6 h after treatment of the cells with 10 ng/ml VT-1, and
the increased levels returned to a 2-fold level at 24 h (Fig. 1A).
TF activity in cell lysates increased in a dose-dependent manner
after treatment of the cells with 0.1 to 10 ng/ml VT-1 for 6 h (Fig.
1B). Up-regulation of TF expression on the cells treated with
10 ng/ml VT-1 was also observed by a semi-quantitative
immunohistochemical assay using anti-TF antibody (Fig. 1C–
E). LPS was not detected in the final VT-1 preparation,
(<0.0005 EU/ml as determined by a Limulus test combined
with chromogenic substrate), in addition, there was no increase
in TF activity when differentiated macrophage-like THP-1 cells
were treated with VT-1 previously boiled for 15 min. The results
indicate that the cellular responses were independent of LPS.
Relative to untreated control cells, a 3.4-fold increase in TF
mRNA levels was observed 2 h after treatment of the
macrophage-like THP-1 cells with 10 ng/ml VT-1, and the
increased levels returned to a 1.4-fold level at 8 h (Fig. 1F). A
concentration-dependent increase in TF mRNA levels was
observed 2 h after treatment of the macrophage-like THP-1 cells
with VT-1 (Fig. 1G). In contrast, no increases in TF activity,
antigen or mRNA levels were observed in the undifferentiated
THP-1 cells after stimulation with 10 ng/ml VT-1 for 2–24 h
(data not shown).r-1, and on the up-regulation of TF mRNA levels in macrophage-like THP-1
various concentrations of MG132, SB203580 or PD98059 for 1 h before
s were incubated with 32P-labeled TF- κB (A-1, B-1, C-1), proximal TF-AP-1
ed according to the method described in Materials and methods. TF mRNA
result and the average relative intensity from three independent experiments.
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of inhibitors on their activations
The human TF promoter gene contains binding sites for NF-
κB/Rel, AP-1, Egr-1 and Sp1 [31]. Activation, nuclear
translocation and composition of these transcription factors in
VT-1-treated macrophage-like THP-1 cells were examined by
EMSA and supershift assays. The results of these assays
indicated that the NF-κB molecules bound to TF-κB oligo had
two bands that consisted of p65 and p50 in the lower band and
p65 and c-Rel in the upper band as a previous study [29].
Additionally, VT-1 activated the AP-1 families including c-Jun,
JunD and c-Fos, and Egr-1 leading to translocation into the
nuclei (data not shown). In contrast, Sp1, Sp3 and Sp4 were
constitutively activated in the cells and were not up-regulated by
VT-1 stimulation (data not shown). Therefore, we decided to
examine the effect of inhibitors on VT-1-induced NF-κB/Rel
binding to TF-κB oligo, AP-1 binding to proximal TF-AP-1
oligo, and Egr-1 binding to Egr-1 oligo (Fig. 2).
In a dose-dependent manner and in parallel with the TF
mRNA levels, VT-1-induced NF-κB/Rel activation was
inhibited by pretreatment of the cells with the proteasome
inhibitor MG132 (Fig. 2A-1 and A-4). However, the VT-1-
induced AP-1 and Egr-1 activations were not influenced by the
MG132 pretreatment (Figs. 2A-2 and 3). When cells were
pretreated with SB203580, an inhibitor for p38 MAPK, VT-1-
induced AP-1 activation was inhibited in a dose-dependent
manner (Fig. 2B-2), but this inhibitor did not affect either the
NF-κB/Rel and Egr-1 activations or the increased TF mRNAFig. 3. Effects of inhibitors on VT-1-induced phosphorylation of IKKα/β, ERK
Phosphorylation of IKKα/β, ERK1/2, p38 MAPK and PI3-kinase in the cell lysate
analyzed by Western blotting. (C) The cells were pretreated with LY294002 (0, 5, 10
were determined by RT-PCR. (D) The cells were pretreated with LY294002 (0, 5, 10 μ
of their kinases was analyzed by Western blotting. The data represent a typical resulevels (Figs. 2B-1, 3 and 4). Pretreatment of the cells with
PD98059, an inhibitor of the mitogen-activated protein kinase
kinase (MEK)/ERK pathway, inhibited the AP-1 and Egr-1
activations and the increase in the TF mRNA levels in VT-1-
stimulated cells in a dose-dependent manner (Figs. 2C-2, 3 and
4); however, there was no change noted for the NF-κB/Rel
activations (Fig. 2C-1). These results indicate that the VT-1-
induced up-regulation of TF mRNA levels occurred in parallel
with the activation of the proteasome/NF-κB/Rel and MEK/
ERK1/2/Egr-1 pathways, but not the p38MAPK/AP-1 pathway.
To further examine the activation of IKKα/β and ERK1/2 in
the VT-1-treated cells, Western blotting was used to detect
phosphorylation of these kinases. Phosphorylation of IKKβ,
ERK2 and p38 MAPK, but not IKKα and ERK1, was observed
in the cells beginning 15 min after the VT-1 stimulation (Fig.
3A). Additionally, phosphorylation of PI3-kinase was transi-
ently observed in the cells at 3 min after VT-1 stimulation (Fig.
3B). Pretreatment of the cells with increasing concentrations of
the PI3-kinase inhibitor, LY294002, inhibited the up-regulation
of TF mRNA levels induced by VT-1 (Fig. 3C) and the
phosphorylations of IKKβ and ERK2 (Fig. 3D).
3.3. Involvement of c-Yes in intracellular signal pathways in
the VT-1-induced up-regulation of TF-mRNA and activity levels
The activation of Src family kinases including c-Yes, c-Src
and Lyn were analyzed in macrophage-like THP-1 cells treated
with or without 10 ng/ml VT-1 (Fig. 4). An approximate 2-fold
increase in the phosphorylation of the enolase substrate by the c-1/2, p38 MAPK and PI3-kinase in macrophage-like THP-1 cells. (A, B)
s prepared from the cells treated with 10 ng/ml VT-1 for indicated times were
μM) for 30 min before stimulation of 10 ng/ml VT-1 for 2 h. TF mRNA levels
M) for 30 min before stimulation of 10 ng/ml VT-1 for 1 h. The phosphorylation
lt and the average relative intensity from three independent experiments.
Fig. 4. Kinetic analysis of Src family kinase activities in macrophage-like THP-1
cells treated with VT-1. Macrophage-like THP-1 cells incubated with or without
VT-1 (10 ng/ml) were lysed at the indicated times. Src family kinase c-Yes (A), c-
Src (B), and Lyn (C) were isolated from each lysate by immunoprecipitation with
anti-c-Yes, anti-c-Src or anti-Lyn antibody and subjected to an in vitro kinase
assay. 32PO4-incorporated c-Yes, c-Src, Lyn and enolase were separated by SDS-
PAGE and exposed to X-ray film. The amount of immunoprecipitated c-Yes, c-
Src, or Lyn protein was assayed by Western blotting with anti-c-Yes, anti-c-Src,
or anti-Lyn. The data represent a typical result and the average relative kinase
activity to phosphorylate enolase from three independent experiments.
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7 min (Fig. 4A). The kinase activity of c-Src also slightly
increased in VT-1-treated cells, although peak activity was not
observed until 30 min after the stimulation (Fig. 4B). No
increase in the activity of Lyn was observed in the VT-1-treated
cells (Fig. 4C).
In order to evaluate involvement of c-Yes in the VT-1-
induced up-regulation of the TF transcription and intracellular
signaling pathway after c-Yes activation, an antisense (AS)
experiment was conducted. Macrophage-like THP-1 cells
treated with specific c-Yes AS for 48 h exhibited a 90%
decrease in c-Yes expression relative to control cells, while
treatment with a random control sense oligo (CS) had no effect
(Fig. 5A). In addition, phosphorylation of PI3-kinase, IKKβ
and ERK2 observed in the VT-1-treated control cells was
attenuated in the c-Yes knockdown cells, but not in the c-Yes
CS-inserted cells, similar to that observed for c-Yes expression
(Fig. 5B, C and D). In contrast, the VT-1-induced phosphoryla-
tion of p38 MAPK observed in the control cells was not
influenced in the c-Yes knockdown and c-Yes CS-inserted cells
(Fig. 5E). Activations of NF-κB/Rel (Fig. 5F) and Egr-1 (Fig.
5G) in VT-1-stimulated cells were also reduced in the c-Yes
knockdown cells, but not in the c-Yes CS cells, with parallel
decreases noted for both TF mRNA levels (Fig. 6A) and activity(Fig. 6B). These results indicate, at least in part, that c-Yes is
essential for up-regulation of TF transcription in VT-1
stimulated macrophage-like THP-1 cells and that c-Yes tyrosine
kinase activity participates in the phosphorylation of PI-3-
kinase, IKKβ and ERK2 and in the activation of the NF-κB/Rel
and Egr-1 pathways. We also investigated the participation of c-
Yes on VT-1-induced TF up-regulation in monocytes, by
constructing c-Yes knockdown cells of adherent monocytes that
were isolated from circulating plasma (Fig. 6C and D). Similar
to macrophage-like THP-1 cells, the adherent monocytes up-
regulated TF mRNA and activity levels in response to VT-1,
with the up-regulation attenuated after insertion of the c-Yes AS
into the cells.
4. Discussion
The present work examined TF expression on differentiated
macrophage-like THP-1 cells, which are widely utilized as
adherent macrophage substitutes, after being exposed to VT-1.
After exposure, there was a transient up-regulation of both TF
activity and expression with increased levels of TF mRNA
along with the retention of cell viability.
The present study was designed to further investigate the
signaling pathways to induce TF up-regulation in the cells
exposed to VT-1. Results indicated that NF-κB/Rel molecules,
AP-1 families, and Egr-1 were activated by VT-1 followed by
translocation into the nuclei. NF-κB/Rel activation is mediated
by proteasomal degradation of IκB phosphorylated by phos-
phoactivated IKKα/β [32]. The present results indicated that
IKKβ, but not IKKα, was predominantly phosphorylated in the
VT-1-stimulated cells and that pretreatment of the cells with
MG132 inhibited the VT-1-induced up-regulation of TF mRNA
levels in parallel with the decreased NF-κB/Rel activation.
Recently, it was reported that activation of NF-κB/Rel to
associate with a selective regulation of major pro-inflammatory
and prothrombotic mediators including TNF-α and TF is
dependent on phosphoactivated IKKβ, but not on IKKα [33].
The current results suggest that VT-1-induced TF transcriptional
up-regulation was mediated at least in part by the IKKβ/
proteasome/NF-κB/Rel pathway.
AP-1 activation is mediated by p38 MAPK, ERKs and/or c-
Jun N-terminal kinase/stress-activated protein kinases [34]. In
the present experiments, phosphorylation of p38 MAPK
occurred after VT-1 treatment of the cells, and pretreatment
with SB203580, a p38 MAPK inhibitor, abolished this VT-1-
induced AP-1 activation. However, up-regulation of TF
transcription was never inhibited, which suggests that AP-1
activation did not directly participate in the up-regulation of TF
mRNA levels.
Egr-1 activation is required for maximal induction of the
TNF-α and TF genes in monocytic cells stimulated with LPS
[35]. Egr-1 is activated by phosphoactivated ERK1/2 [36]. It
has been reported that hypoxia-induced Egr-1 activation in
endothelial cells [37] and the toxin Malachite Green-induced
malignant transformation in hamster embryo cells is dependent
on phosphoactivation of ERK2, but not ERK1 [38], suggesting
that there is a distinct phosphoactivation of ERKs in various
Fig. 5. Effect of c-Yes knockdown on VT-1-induced phosphorylation of kinases and activation of TF-κB/Rel, Egr-1 and AP-1 in macrophage-like THP-1 cells. (A)
Macrophage-like THP-1 cells were incubated with or without specific c-Yes antisense (c-Yes AS) or random control sense (CS) oligonucleotide (4 μM) for 24 or 48 h.
The cells were solubilized and c-Yes protein in cell lysates was analyzed by Western blotting. (B, C, D, E, F, G, H) The cells treated with c-Yes AS or CS were further
incubated with or without 10 ng/ml VT-1 for 5 min (B), 1 h (C–E) or 2 h (F–H). The cell lysates and nuclear proteins extracted from the cells were analyzed byWestern
blotting (B–E) and by EMSA (F–H). The data represent a typical result and the average relative intensity from three independent experiments.
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activation [39]. The present results indicated that ERK2 was
predominantly phosphorylated by VT-1 treatment of the cells
and that PD98059 pretreatment of the cells inhibited the VT-1-
induced up-regulation of the TF mRNA levels in a parallel withFig. 6. Effect of c-Yes knockdown on VT-1-induced TF mRNA levels and TF
Macrophage-like THP-1 cells (1×106 cells/well) were incubated with or without
monocytes (0.65×106 cells/well) were incubated with or without c-Yes AS or CS o
without 10 ng/ml VT-1 for 2 h (A, C) or 6 h (B, D). The data represent a typic
activities expressed as the mean±S.D. (B, D) from four independent experiments. TEgr-1 inhibition. This suggests that the VT-1-induced up-
regulation of TF transcription may be dependent upon the
MEK/ERK2/Egr-1 pathway.
The VT-1 receptor, Gb3, is a glycosphingolipid (GSL). GSLs
are known to form microdomains containing cholesterol at theactivities in macrophage-like THP-1 cells and adherent monocytes. (A, B)
c-Yes AS or CS oligonucleotide (4 μM) for 24 or 48 h. (C, D) Adherent
ligonucleotide (4 μM) for 24 or 48 h. The cells were further incubated with or
al result and the average relative intensity (A, C), and the TF procoagulant
he statistical differences were analyzed by Student's t-tests; *<0.05, **<0.01.
842 K. Murata et al. / Biochimica et Biophysica Acta 1762 (2006) 835–843surface of the plasma membranes. Since the GSL microdomains
are associated with a variety of signaling molecules, such as the
Src family kinases, they are postulated to be involved in signal
transduction. It has been reported that VT-1 bound to Gb3 on the
surface of the human renal tubular-derived ACHN cell line leads
to the association of Gb3 with c-Yes [13]. In the present study, it
was observed that within 3 min of VT-1 stimulation of the
macrophage-like THP-1 cells, c-Yes tyrosine kinase was quickly
activated and within 30 min, was followed by a slow activation
of c-Src without activation of Lyn. Therefore, we constructed c-
Yes knockdown macrophage-like THP-1 cells to evaluate the
participation of c-Yes in the up-regulation of TF by VT-1.
The present work revealed that PI3-kinase was quickly
phosphorylated after VT-1 stimulation of macrophage-like THP-
1 cells and that the VT-1-induced phosphorylations of IKKβ and
ERK2 along with the up-regulation of TF transcription were
inhibited by pretreatment of the cells with the PI3-kinase
inhibitor, LY294002. Furthermore, phosphorylations of PI3-
kinase, IKKβ and ERK2, activations of NF-κB/Rel and Egr-1,
and increased TF mRNA and activity levels observed in VT-1-
treated control cells were suppressed by the c-Yes knockdown in
a parallel with the reduced expression of c-Yes. However,
phosphorylation of p38MAPK and activation of AP-1 in the VT-
1-treated control cells was not affected by c-Yes knockdown or
LY294002 treatment. Overall, the present results suggest that, at
least in part, VT-1 stimulation activated c-Yes and the activated
c-Yes up-regulated TF transcription through activations of the
PI3-kinase/IKKβ/proteasome/NF-κB/Rel and PI3-kinase/
MEK/ERK2/Egr-1 pathways. This is the first report of a protein
whose expression is controlled by c-Yes activated by VT-1
stimulation and TF expression that is mediated by activated c-
Yes. On the other hand, a slow and slight activation of c-Src was
observed in the present work. Therefore, with the exception of
Lyn, we cannot rule out participation of Src family kinases other
than c-Yes in the VT-1 induction of TF transcription.
We further constructed c-Yes knockdown adherent mono-
cytes and observed that these knockdown monocytes also
suppressed the increase in TF mRNA and the activity levels
observed in VT-1-treated control cells. This indicates that VT-1-
induced TF up-regulation in adherent monocytes, as well as
macrophages, could possibly be regulated by c-Yes activation.
The cytokine Oncostatin M has been found to activate the
tyrosine phosphorylation signal transduction pathway via the
activation of c-Yes in endothelial cells [40] and also induces
increased synthesis of TF in human vascular smooth muscle
cells [41]. Activated Src family proteins, including c-Yes and
p60src, activate PI3-kinase [42], and the activated PI3-kinase
activates Egr-1 through ERK1/2 activation, which then induces
NF-κB activation through the activation of the PI3-kinase/Akt/
IκB kinase pathway [43,44]. However, studies on the role of the
PI3-kinase/Akt pathway in NF-κB- and ERK1/2-dependent
gene expression are controversial. It has been reported that
inhibition of the PI3-kinase/Akt pathway by pretreating
monocytes with LY294002 enhances LPS-induced up-regula-
tion of TF mRNA levels through Egr-1 and NF-κB activation
via activation of ERK1/2 and enhanced nuclear translocation of
p65, respectively [45]. In preliminary experiments, we observedthat LPS-induced up-regulation of TF in macrophage-like THP-
1 cells was not attenuated in the c-Yes knockdown cells (data
not shown). This implies that the up-regulation may not be
mediated by c-Yes activation, which is in contrast to the effects
observed for VT-1 on TF expression.
In addition to the VT-1-induced up-regulation of TF activity
that is demonstrated in the present work, it has also recently been
reported that the TF–VIIa–Xa ternary complex formed on the
surface of macrophage/monocyte lineage and/or released Xa
induces production of inflammatory cytokines such as IL-1, 6
and 8 via PAR1 and 2 activation [16,46,47]. These cytokines
also induce TF expression on macrophage/monocytes [19,20].
Thus, VT-1-stimulated macrophage/monocyte lineage may
additively or synergistically amplify TF overexpression on
cells through the stimulation of autocrine inflammatory cytokine
responses. During the coagulation–inflammation–thrombosis
circuit, overexpression of TF on the macrophage/monocyte
lineage may play an important role in the development of disease
complications, such as HUS and CNS vascular damage.
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